相关临床试验
1277
322 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1905
终止
15
1.2%
招募中
401
31.4%
暂停
2
0.2%
Available
1
0.1%
撤回
11
0.9%
进行中（未招募）
68
5.3%
Unknown
295
23.1%
已完成
230
18.0%
Enrolling By Invitation
7
0.6%
尚未招募
247
19.3%
暂无批准数据
- A Chinese multi-center trial published in the New England Journal of Medicine demonstrates that neoadjuvant therapy combining Gemox chemotherapy, targeted therapy, and immunotherapy significantly improves outcomes for intrahepatic cholangiocarcinoma patients. - The study of 178 patients showed median event-free survival of 18 months with the drug cocktail versus 8.7 months with surgery alone, representing more than a doubling of disease-free time. - The neoadjuvant protocol achieved a 55% objective response rate and improved 24-month survival rates to 79% compared to 61% for surgery-only patients. - This breakthrough offers a new standard of care for a disease with historically poor outcomes, where five-year survival rates after surgery range from only 25% to 40%.
- Chinese researchers successfully developed the first technique to efficiently differentiate human pluripotent stem cells into A10 subtype dopamine neurons, marking a breakthrough in cell therapy for psychiatric disorders. - When transplanted into depression-model mice, the engineered A10 neurons integrated into host neural circuits and significantly reduced anxiety and depression-like behaviors while restoring pleasure-seeking ability. - The study demonstrates proof-of-concept for targeted neural circuit reconstruction as a potential alternative to traditional antidepressants, which affect approximately one-third of treatment-resistant depression patients poorly.
- Bio-Thera Solutions' BAT4406F, an ADCC-enhanced anti-CD20 monoclonal antibody, demonstrated statistically significant efficacy in treating neuromyelitis optica spectrum disorder (NMOSD) during interim analysis of its pivotal Phase II/III trial. - The Independent Data Monitoring Committee recommended early termination of the 45-site Chinese trial due to compelling efficacy results that met pre-defined superiority criteria. - Bio-Thera has closed patient enrollment ahead of schedule and will begin preparing regulatory approval submissions to China's NMPA for this rare autoimmune disease affecting optic nerves and spinal cord. - The breakthrough addresses a critical unmet medical need for NMOSD patients, who face devastating outcomes including permanent blindness, paralysis, and progressive disability with limited current treatment options.
- Singlera Genomics and Fudan University's Zhongshan Hospital published results from the GUIDE prospective cohort study in Molecular Cancer, demonstrating their GutSeer assay's ability to detect five major gastrointestinal cancers through a simple blood test. - The DNA methylation-based assay achieved 81.5% sensitivity and 94.4% specificity for cancer detection, with 66.4% of cancer patients in the cohort being early-stage (stage I/II). - GutSeer outperformed a low-pass WGS fragmentomics assay with an AUC of 0.963 versus 0.887, while also determining tissue-of-origin in 80.7% of cases and detecting 21.4% to 47.1% of precancerous lesions.
- A novel multimodal fusion (MMF) system combining CT imaging-based deep learning with clinical features achieved C-index values of 0.74 for overall survival and 0.69 for progression-free survival in predicting outcomes for unresectable hepatocellular carcinoma patients receiving immune checkpoint inhibitors. - The MMF system outperformed traditional assessment methods by 29.8% for overall survival prediction compared to mRECIST criteria and demonstrated consistent risk stratification across diverse clinical subgroups in a multicenter validation study of 859 patients. - Biological analysis revealed the system's predictions correlate with key molecular pathways including PI3K-Akt signaling and tumor suppressor genes like GCK, providing mechanistic insights into immunotherapy response patterns in hepatocellular carcinoma.
- Finnish longitudinal study reveals children with higher physical fitness levels develop better cognitive abilities and experience lower rates of depression and stress as teenagers. - Researchers tracked 241 children over eight years, finding that shuttle sprint performance in childhood positively correlated with improved mental health outcomes in adolescence. - Experts recommend increased physical activity participation in schools and leisure settings, while noting excessive screen time may diminish the mental health benefits of fitness.
- A phase 2 trial demonstrates manageable safety profile of serplulimab combined with bevacizumab biosimilar HLX04 as first-line treatment for advanced hepatocellular carcinoma. - The combination therapy achieved a 29.3% objective response rate and median overall survival of 20.4 months, showing promising antitumor activity in treated patients. - While 98.4% of patients experienced treatment-emergent adverse events, only 27.9% were serious, with grade 5 events occurring in just 4.9% of patients.
- The NSABP B-59 trial showed that adding atezolizumab to neoadjuvant chemotherapy did not significantly improve event-free survival in stage II-III TNBC. - The CamRelief trial in China demonstrated a significant improvement in pathologic complete response with camrelizumab plus chemotherapy for TNBC. - Neither trial demonstrated improvement in overall survival or other survival endpoints, raising questions about pCR as a surrogate for long-term benefit. - Differences in trial design, patient characteristics, and drugs may explain the mixed efficacy signals observed in neoadjuvant immunotherapy for TNBC.
- Wegovy, a weight-loss drug containing semaglutide, has been introduced in China, offering a new treatment option for the country's increasing obese population. - Clinical data indicates Wegovy can achieve an average weight reduction of approximately 17% over 18 months, marking a significant advancement in obesity management. - China's national health authority emphasizes a multidisciplinary approach to obesity, including medication, lifestyle changes, and increased physical activity. - Experts caution that weight-loss drugs like Wegovy are not a quick fix and should be combined with healthy lifestyle choices for optimal and sustainable results.
